title: Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.
abstract: Francisella tularensis, a Gram-negative bacterium, is the causative agent of tularemia. No licensed vaccine is currently available for protection against tularemia, although an attenuated strain, dubbed the live vaccine strain (LVS), is given to at-risk laboratory personnel as an investigational new drug (IND). In an effort to develop a vaccine that offers better protection, recombinant attenuated derivatives of a virulent type A strain, SCHU S4, were evaluated in New Zealand White (NZW) rabbits. Rabbits vaccinated via scarification with the three attenuated derivatives (SCHU S4 ΔguaBA, ΔaroD, and ΔfipB strains) or with LVS developed a mild fever, but no weight loss was detected. Twenty-one days after vaccination, all vaccinated rabbits were seropositive for IgG to F. tularensis lipopolysaccharide (LPS). Thirty days after vaccination, all rabbits were challenged with aerosolized SCHU S4 at doses ranging from 50 to 500 50% lethal doses (LD50). All rabbits developed fevers and weight loss after challenge, but the severity was greater for mock-vaccinated rabbits. The ΔguaBA and ΔaroD SCHU S4 derivatives provided partial protection against death (27 to 36%) and a prolonged time to death compared to results for the mock-vaccinated group. In contrast, LVS and the ΔfipB strain both prolonged the time to death, but there were no survivors from the challenge. This is the first demonstration of vaccine efficacy against aerosol challenge with virulent type A F. tularensis in a species other than a rodent since the original work with LVS in the 1960s. The ΔguaBA and ΔaroD SCHU S4 derivatives warrant further evaluation and consideration as potential vaccines for tularemia and for identification of immunological correlates of protection.
authors.affiliation: Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Douglas S
authors.initials: DS
authors.lastname: Reed
authors.forename: Le'kneitah P
authors.initials: LP
authors.lastname: Smith
authors.forename: Kelly Stefano
authors.initials: KS
authors.lastname: Cole
authors.forename: Araceli E
authors.initials: AE
authors.lastname: Santiago
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Mann
authors.forename: Eileen M
authors.initials: EM
authors.lastname: Barry
mesh_terms: D000336:Aerosols; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D005260:Female; D005604:Francisella tularensis / Q000276:immunology* / Q000472:pathogenicity*; D019570:Inhalation Exposure; D011817:Rabbits; D014406:Tularemia / Q000517:prevention & control / Q000662:veterinary*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D014774:Virulence
chemical_list: D000336:Aerosols; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated